HOOK (HOOKIPA Pharma) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 11, 2026)


HOOK HOOKIPA Pharma Inc HOOK
50 GF Score
Price $1.15
View Full Analysis

What is HOOKIPA Pharma 5-Year Yield-on-Cost %?

HOOKIPA Pharma HOOK 50 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus rates HOOK with a GF Score™ of 50/100. Among 153 Biotechnology companies, HOOKIPA Pharma ranks worse than 653594.12% on this metric.

HOOKIPA Pharma's yield on cost for the quarter that ended in Jun. 2025 was 0.00.


The historical rank and industry rank for HOOKIPA Pharma's 5-Year Yield-on-Cost % or its related term are showing as below:



HOOK's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.65
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

HOOKIPA Pharma  (OTCPK:HOOK) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


HOOKIPA Pharma 5-Year Yield-on-Cost % Related Terms


HOOK vs COCP, LNAI, CYCN: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, HOOKIPA Pharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HOOKIPA Pharma 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's 5-Year Yield-on-Cost % falls into.


HOOK
50GF Score
HOOKIPA Pharma Inc HOOK
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HOOKIPA Pharma 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of HOOKIPA Pharma is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
HOOKIPA Pharma (HOOK) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on HOOKIPA Pharma and its competitors. According to the industry distribution chart, HOOKIPA Pharma ranks #999999 out of 153 companies in the Biotechnology industry.
Is HOOKIPA Pharma's 5-Year Yield-on-Cost % too high?
HOOKIPA Pharma's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, HOOKIPA Pharma ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's 5-Year Yield-on-Cost % compare to COCP and LNAI?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places HOOKIPA Pharma in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.65, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on HOOKIPA Pharma and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOOKIPA Pharma's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score

Get the complete analysis for HOOK

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price